Challenges and Advances in Blood Thinner Use

Larry Bordeaux, a 65-year-old from Havelock, North Carolina, has been relying on blood thinners since 2010 when he developed life-threatening clots after surgery. He acknowledges that these medications have been lifesaving. However, when he must cease taking them temporarily before medical treatments, he quickly experiences clotting, highlighting the precarious nature of such medications. Despite their benefits, blood thinners expose him to significant risks, such as serious and uncontrolled bleeding. Bordeaux has faced complications ranging from a substantial hematoma—a condition where blood pools outside the blood vessels—to gastrointestinal bleeding.

“Even simple falls can be dangerous for me if my blood thinner dosage isn’t managed correctly. I could end up with severe bleeding,” Bordeaux explained. His connection with the National Blood Clot Alliance reflects his commitment to reducing risks associated with blood clots and adverse events linked to blood thinners.

Bordeaux’s experience is not unique; he is among more than 8 million individuals in the U.S. who are prescribed blood thinners, also called anticoagulants, primarily due to clots developed post-surgery or an age-related heart disorder known as atrial fibrillation. While necessary for preventing strokes and embolisms by interrupting natural clotting processes, these drugs can also lead to dangerous bleeding incidents. These incidents result in numerous hospital visits for older patients annually, costing the healthcare system over $2.5 billion, according to the American Journal of Medicine.

Dr. Samin Sharma, director of the Cardiovascular Clinical Institute at Mount Sinai Fuster Heart Hospital, remarked on the dual nature of these drugs, highlighting their role in diminishing the risk of ischemic strokes but increasing the likelihood of hemorrhagic strokes. These types of strokes are caused by bleeding as opposed to blockages.

Even prominent figures like President Donald Trump have commented on such risks concerning medications like aspirin, which he takes regularly and acknowledges causes bruising.

Dr. Pieter Cohen from Harvard University emphasized that bleeding in the gastrointestinal tract is a significant concern, often necessitating hospitalization or blood transfusions in severe cases. Patients can also suffer from heavy bleeding due to minor injuries, nosebleeds, blood in urine, or, in rare cases, brain hemorrhages.

Arthur Allen, the president-elect of the Anticoagulation Forum, pointed out the increased risk of blood loss in individuals taking anticoagulants and the necessity for possible transfusions, often resulting in poorer outcomes. Despite these potential harms, advocates suggest that many patients are unaware of the risks associated with blood thinners. Leslie Lake, president of the National Blood Clot Alliance, notes that bleeding events are not uncommon, but they are frequently overlooked as mere complications instead of being seen as preventable harms.

A New Generation of Blood Thinners

Historically, warfarin was the predominant anticoagulant, known for its inconsistencies and requirement for frequent blood testing. Since 2010, a new class of blood thinners called direct oral anticoagulants (DOACs) has emerged, including medications like apixaban, dabigatran, edoxaban, and rivaroxaban, showing improved safety and consistency compared to warfarin.

However, despite these advances, the anticipated improvement in safety has not fully materialized. Annually, approximately 300,000 individuals using anticoagulants experience bleeding requiring emergency treatment—a figure comparable to those using warfarin. Some experts, like Allen, note that the reduced monitoring requirements of newer drugs might lead to overmedication or prolonged prescriptions, particularly when combined inappropriately with antiplatelet drugs, contributing to a heightened risk.

Johnson & Johnson and Daiichi Sankyo, makers of Xarelto and Savaysa respectively, acknowledge the risks, emphasizing that patients should understand potential bleeding risks when using their medications. The risks of drug interactions, especially with over-the-counter medications like aspirin, are also a concern, as indicated by a Michigan study showing a common overlap in usage that could lead to severe adverse effects.

Correct dosing remains a crucial factor, particularly as patients age and factors such as kidney function and risk of falling change. Dr. Sabine von Preyss-Friedman stresses the need for improved patient education to prevent serious outcomes from incorrect dosing or drug interactions.

Balancing Risks

Determining whether to prescribe anticoagulants involves assessing both bleeding and stroke risks. Dr. Sharma emphasizes that if bleeding risk outweighs the benefit, anticoagulants might not be the right choice. However, care must be taken not to underprescribe due to fear of bleeding when therapy could prevent strokes.

Some hospitals now use predictive models to assist doctors with patient risk assessments concerning strokes and bleeding. Using artificial intelligence, these tools help determine proper dosages and monitoring needs, potentially enhancing patient safety. Dr. Toby Trujillo highlighted how such technologies are being integrated into health systems to flag patients requiring specialist consultations.

Furthermore, research into treatments like ablation for atrial fibrillation and new anticoagulants targeting specific proteins linked to clotting aims to reduce bleeding risks. These investigational Factor XIa inhibitors show promise in maintaining efficacy while potentially offering a safer profile.

Experts like Allen and Von Preyss-Friedman believe enhanced management and emerging therapies could considerably mitigate bleeding events, improving outcomes for thousands. “There’s much potential to prevent emergency department visits and severe complications by managing these medications effectively,” Von Preyss-Friedman concluded.